Tropifexor is a novel and potent Farnesoid X Receptor (FXR) agonist that has demonstrated high efficacy in treating liver diseases, such as non-alcoholic steatohepatitis (NASH), by reducing liver inflammation and fibrosis (Chen et al., 2022a). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.